Exited position

Stanley Druckenmiller’s Merck (MRK) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Duquesne Family OfficeVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ4 2011Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares2.36MHighest verified quarter-end share count
Quarters reported11Verified quarters with shares above zero
What happened?

Duquesne Family Office first reported Merck in Q4 2011. The reported position was increased across later filings. The latest verified relationship event shows that Duquesne Family Office sold the entire position in Q3 2019, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q3 2019
Sold the entire position−467.20K shares · No shares reported at quarter-end
Q2 2019
Bought 75.4% more+200.90K shares · 467.20K shares reported after the change
Filing context

Quarter-end price $83.85 · Estimated holding basis $83.46

Q1 2019
New position+266.30K shares · 266.30K shares reported
Filing context

Quarter-end price $83.17 · Estimated holding basis $83.17

Q3 2017
Sold the entire position−755.50K shares · No shares reported at quarter-end
Q2 2017
New position+755.50K shares · 755.50K shares reported
Filing context

Quarter-end price $64.09 · Estimated holding basis $64.09

Q1 2017
Sold the entire position−683.80K shares · No shares reported at quarter-end

2 unchanged quarters are collapsed by default.

Portfolio importance

How important was Merck in Duquesne Family Office’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight1.2%Q2 2019
Last reported rank#28of 60 reported positions
Peak portfolio weight7.5%Q4 2012
Best historical rank#4Q4 2012
At peak importanceQ4 2012
MRK
7.5%
Largest holding
9.1%
Cross-investor discovery

Who else owns Merck?

Also reported by 4 other tracked investors in their latest verified filings.

Christopher BloomstranSemper Augustus Investments Group LLC
MRK0.6% of reported portfolio
Joel GreenblattGotham Asset Management
MRK0.2% of reported portfolio
Ray DalioBridgewater Associates, LP
MRK0.0% of reported portfolio
Explore Merck across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$143.932026-09-11

Market context only; not an investor transaction price.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

View Merck stock page →

This tracker follows Duquesne Family Office LLC’s Form 13F disclosures—not Stanley Druckenmiller’s personal brokerage account. Form 13F reports quarter-end U.S.-listed positions and certain options, but it does not reveal exact trade dates, execution prices, short positions or the purpose of an option position.